Case Report

Anti-Immunoglobulin E in the Treatment of Refractory Atopic Dermatitis

Authors: David Amrol, MD

Abstract

Atopic dermatitis (AD) is a common diagnosis seen in both children and adults, and it is often the first manifestation of atopic disease. Research has shown a strong correlation between serum IgE levels, the severity of atopic dermatitis, and co-existing asthma and/or allergic rhinitis.18 Omalizumab (Xolair®, East Hanover, NJ; Genentech, South San Francisco, CA) is a monoclonal antibody to human IgE and is currently Food and Drug Administration (FDA) approved for the treatment of asthma. We present 3 patients with severe, treatment resistant atopic dermatitis whose cutaneous symptoms significantly improved by treatment with omalizumab.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.Boguniewicz M. Atopic dermatitis: beyond the itch that rashes. Immunol Allergy Clin North Am 2005;25:333–351, vii.
 
2.Boguniewicz M, Schmid-Grendelmeier P, Leung DY. Atopic dermatitis. J Allergy Clin Immunol 2006;118:40–43.
 
3.Habif TP. Atopic Dermatitis, in Habif TP (ed): Clinical Dermatology: A Color Guide to Diagnosis and Therapy. St. Louis, Missouri, Mosby, Inc., 2004, ed 4, pp 107–114, 121–127.
 
4.Boguniewicz M, Lueng DY. Adkinson: Middleton's Allergy: Principles and Practice. St. Louis, Missouri, Mosby, Inc., 2003, ed 6.
 
5.Citation removed in proof.
6.Lim H. Eczema. Cecil Textbook of Medicine. Philadelphia, PA, W.B. Saunders Company. 2004, ed 22, pp 2459–2460.
7.Vigo P, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006;55:168–170.
 
8.Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol 2005;53(1 suppl 1):S3–S16.
 
9.Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361:151–160.
 
10.Nelson RP Jr, Ballow M. 26. Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies. J Allergy Clin Immunol 2003;111(2 suppl):S720–S743.
 
11.Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53:338–340.
 
12.Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54:68–72.
 
13.Ruffin CG, Busch BE. Omalizumab: a recombinant humanized anti-IgE antibody for allergic asthma. Am J Health Syst Pharm 2004;61:1449–1459.
 
14.Dibbern DA. Urticaria: selected highlights and recent advances. Med Clin North Am. 2006;90:187–209.
 
15.Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:1223–1225.
 
16.Citation removed in proof.
 
17.Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008;29:530–537.
 
18.Kunz B, Oranje AP, Labrèze L. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10–19.
 
19.Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23–31.
 
20.Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788–797.
 
21.Jones HE, Inouye JC, McGerity JL. Atopic disease and serum immunoglobulin-E. Br J Dermatol 1975;92:17–25.